No CrossRef data available.
Article contents
Lamotrigine-Associated Depersonalization Symptoms
Published online by Cambridge University Press: 07 November 2014
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Letters
- Information
- Copyright
- Copyright © Cambridge University Press 2010
References
1. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/020241s037s038,020764s030s031lbl.pdf. Accessed August 26, 2009.Google Scholar
2.Wang, SJ, Sihra, TS, Gea, PW. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuropharmacol Neurotoxicol. 2001; 12(10): 2255–2258.Google ScholarPubMed
3.Anand, A, Charney, DS, Oren, D, et al. Attenuation of neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry. 2000; 57: 270–276.CrossRefGoogle ScholarPubMed
4.Sierra, M, Phillips, M, Ivin, G, et al. A placebo-controlled, cross-over trial of Lamotrigine in depersonalization disorder. J Psychopharmacol. 2003; 17(1): 103–105.CrossRefGoogle ScholarPubMed
5.Medford, N, Sierra, M, Baker, D, David, A. Understanding and treating depersonalization disorder. Advances in Psychiatric Treatment. 2005; 11: 92–100.CrossRefGoogle Scholar
6.Sarkar, J, Jones, N, Sullivan, G. A case of depersonalization-derealization syndrome during treatment with Quetiapine. J Psychopharmacol. 2001; 15(3): 209–211.CrossRefGoogle ScholarPubMed
7.Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239–245.CrossRefGoogle ScholarPubMed
You have
Access